Adjuvant Nivolumab vs Observation in Resected Non–Small Cell Lung Cancer
This randomized clinical trial examines whether adjuvant nivolumab improves disease-free survival and overall survival in patients with resected non–small cell lung cancer with any tumor programmed death-ligand 1 expression.
Original Source
Read the full article at Jamanetwork →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.